E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats.
Surapaneni, Dinesh Kumar, Adapa, Sree Rama Shiva Shanker, Preeti, Kumari et al. · Journal of ethnopharmacology · 2012 · DOI
Quick Summary
Researchers tested a natural substance called shilajit in rats with fatigue symptoms similar to ME/CFS. The shilajit appeared to reduce fatigue-like behaviors and anxiety, and improved how well the rats' cells produced energy. This suggests shilajit might work by helping the body's stress response system and protecting mitochondria—the 'powerhouses' inside cells.
Why It Matters
This study identifies mitochondrial dysfunction and HPA axis dysregulation as potential therapeutic targets in ME/CFS, suggesting natural compounds may modulate these pathways. If validated in human studies, it could open new avenues for treating fatigue and post-exertional malaise, two hallmark symptoms of ME/CFS.
Observed Findings
- Shilajit reversed CFS-induced increase in immobility time and decrease in climbing behavior.
- Shilajit attenuated anxiety-like responses in the elevated plus maze test.
- Shilajit normalized plasma corticosterone levels and adrenal gland weight reduced by CFS.
- Shilajit preserved mitochondrial enzyme complex activities (I, II, IV, V) and membrane potential in the prefrontal cortex.
- Shilajit reduced mitochondrial oxidative stress markers (nitric oxide, lipid peroxidation) and enhanced antioxidant enzyme activity.
Inferred Conclusions
- Shilajit mitigates behavioral and physiological CFS-like symptoms through modulation of the HPA axis.
- Mitochondrial preservation and restoration of bioenergetic function may be a key mechanism by which shilajit improves fatigue-related outcomes.
- Mitochondria represent a viable therapeutic target for developing CFS treatments.
Remaining Questions
- Does shilajit produce similar effects in human ME/CFS patients, and what are appropriate doses?
- Which active components of shilajit (DBPs, DCPs, fulvic acids) are most responsible for the observed mitochondrial and HPA axis effects?
What This Study Does Not Prove
This rat model does not prove that shilajit will be effective or safe in humans with ME/CFS. The forced-swim stress model may not capture the full complexity of human ME/CFS pathology, and findings cannot be directly extrapolated to clinical outcomes without human trials.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionExploratory Only
Metadata
- DOI
- 10.1016/j.jep.2012.06.002
- PMID
- 22771318
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →